Preeclampsia, a Disease of the Maternal Endothelium: The Role of Antiangiogenic Factors and Implications for Later Cardiovascular Disease
暂无分享,去创建一个
R. Levine | S. Karumanchi | Camille E. Powe | C. Powe | Ananth A Karumanchi | Camille E. Powe | A. Karumanchi
[1] L. Vatten,et al. Preeclampsia, Soluble Fms-like Tyrosine Kinase 1, and the Risk of Reduced Thyroid Function: Nested Case-Control and Population-based Study , 2011 .
[2] R. Romero,et al. Circulating angiogenic and antiangiogenic factors in women with eclampsia. , 2011, American journal of obstetrics and gynecology.
[3] I. Barshack,et al. Metabolic , Endocrine and Genitourinary Pathobiology Effects of Hypoxia-Inducible Factor-1 Overexpression in Pregnant Mice Possible Implications for Preeclampsia and Intrauterine Growth Restriction , 2010 .
[4] J. Kingdom,et al. Vascular Dysfunction in Women With a History of Preeclampsia and Intrauterine Growth Restriction: Insights Into Future Vascular Risk , 2010, Circulation.
[5] Randy J Read,et al. A redox switch in angiotensinogen modulates angiotensin release , 2010, Nature.
[6] L. Vatten,et al. Hypertension in Pregnancy and Later Cardiovascular Risk: Common Antecedents? , 2010, Circulation.
[7] Y. Jang,et al. Soluble fms-like tyrosine kinase-1 and the progression of carotid intima-media thickness – 24-month follow-up study –. , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[8] C. Sartori,et al. Pulmonary and Systemic Vascular Dysfunction in Young Offspring of Mothers With Preeclampsia , 2010, Circulation.
[9] A. Hingorani,et al. Prospective Study of Placental Angiogenic Factors and Maternal Vascular Function Before and After Preeclampsia and Gestational Hypertension , 2010, Circulation.
[10] K. Lim,et al. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome , 2010, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[11] Mitsuaki Suzuki,et al. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia , 2010, Hypertension Research.
[12] N. Brown,et al. Increased Sensitivity to Angiotensin II Is Present Postpartum in Women With a History of Hypertensive Pregnancy , 2010, Hypertension.
[13] R. Levine,et al. How does smoking reduce the risk of preeclampsia? , 2010, Hypertension.
[14] G. Saade,et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. , 2010, The New England journal of medicine.
[15] S. Karumanchi,et al. Placental Vasculature in Health and Disease , 2010, Seminars in thrombosis and hemostasis.
[16] J. Folkman,et al. Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. , 2010, The Journal of pediatrics.
[17] Trimble,et al. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: preeclampsia. , 2010, American journal of obstetrics and gynecology.
[18] J. Dudenhausen,et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. , 2010, American journal of obstetrics and gynecology.
[19] S. Karumanchi,et al. Recombinant Vascular Endothelial Growth Factor 121 Infusion Lowers Blood Pressure and Improves Renal Function in Rats With Placental Ischemia-Induced Hypertension , 2010, Hypertension.
[20] A. Gruber,et al. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model , 2009, Journal of cellular and molecular medicine.
[21] B. Sibai,et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. , 2010, American journal of obstetrics and gynecology.
[22] L. Vatten,et al. Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study , 2009, BMJ : British Medical Journal.
[23] R. Romero,et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia , 2009, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[24] H. Pavenstädt,et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. , 2009, Journal of the American Society of Nephrology : JASN.
[25] John C Chappell,et al. Local guidance of emerging vessel sprouts requires soluble Flt-1. , 2009, Developmental cell.
[26] K. Boström,et al. Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. , 2009, Blood.
[27] H. Hurwitz,et al. Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression , 2009, Hypertension.
[28] Kang Z. Liu,et al. A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia. , 2009, The Journal of clinical endocrinology and metabolism.
[29] B. Sibai,et al. Hypertensive Pregnancy Disorders and Subsequent Cardiovascular Morbidity and Type 2 Diabetes Mellitus in the Mother , 2009, Hypertension.
[30] B. Sibai,et al. Diagnosis and management of atypical preeclampsia-eclampsia. , 2009, American journal of obstetrics and gynecology.
[31] L. Poston,et al. World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre‐eclampsia in populations of low nutritional status from developing countries , 2009, BJOG : an international journal of obstetrics and gynaecology.
[32] C. Berg,et al. Overview of Maternal Morbidity During Hospitalization for Labor and Delivery in the United States: 1993–1997 and 2001–2005 , 2009, Obstetrics and gynecology.
[33] M. Saint-Geniez,et al. TGF-β Is Required for Vascular Barrier Function, Endothelial Survival and Homeostasis of the Adult Microvasculature , 2009, PloS one.
[34] L. Florea,et al. Novel splice variants of sFlt1 are upregulated in preeclampsia. , 2009, Placenta.
[35] S. Wen,et al. Utilization of Health Care Services of Pregnant Women Complicated by Preeclampsia in Ontario , 2009, Hypertension in pregnancy.
[36] I. Sargent,et al. Circulating Platelet-derived and Placenta-derived Microparticles Expose Flt-1 in Preeclampsia , 2008, Reproductive Sciences.
[37] R. Levine,et al. Circulating soluble endoglin and placental abruption , 2008, Prenatal diagnosis.
[38] Tiejuan Mi,et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice , 2008, Nature Medicine.
[39] J. Tanus-Santos,et al. Nitric Oxide Formation Is Inversely Related to Serum Levels of Antiangiogenic Factors Soluble Fms-Like Tyrosine Kinase-1 and Soluble Endogline in Preeclampsia , 2008, Hypertension.
[40] D. Nochy,et al. VEGF inhibition and renal thrombotic microangiopathy. , 2008, The New England journal of medicine.
[41] E. Norwitz,et al. Fractional Excretion of Tumor Necrosis Factor-&agr; in Women With Severe Preeclampsia , 2008, Obstetrics and gynecology.
[42] S. Yagel,et al. A Novel Human-Specific Soluble Vascular Endothelial Growth Factor Receptor 1: Cell Type-Specific Splicing and Implications to Vascular Endothelial Growth Factor Homeostasis and Preeclampsia , 2008, Circulation research.
[43] Liang Xie,et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia , 2008, Nature.
[44] R. Ness,et al. C-Reactive Protein Is Elevated 30 Years After Eclamptic Pregnancy , 2008, Hypertension.
[45] M. Petri,et al. Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. , 2008, The Journal of rheumatology.
[46] G. Demetri,et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. , 2008, Journal of the National Cancer Institute.
[47] N. Himes,et al. VEGF and TGF-β are required for the maintenance of the choroid plexus and ependyma , 2008, The Journal of experimental medicine.
[48] T. Konno,et al. Maternal hypoxia activates endovascular trophoblast cell invasion. , 2008, Developmental biology.
[49] Chie-Pein Chen,et al. Pre‐eclampsia is associated with dendritic cell recruitment into the uterine decidua , 2008, The Journal of pathology.
[50] B. Sibai,et al. Antioxidant therapy to prevent preeclampsia: a randomized controlled trial. , 2008, Obstetrics and gynecology.
[51] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[52] J. Granger,et al. Hypertension Produced by Reduced Uterine Perfusion in Pregnant Rats Is Associated With Increased Soluble Fms-Like Tyrosine Kinase-1 Expression , 2007, Hypertension.
[53] A. Hingorani,et al. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis , 2007, BMJ : British Medical Journal.
[54] N Stephen Pollitt,et al. Recombinant Vascular Endothelial Growth Factor 121 Attenuates Hypertension and Improves Kidney Damage in a Rat Model of Preeclampsia , 2007, Hypertension.
[55] S. Karumanchi,et al. The glomerular injury of preeclampsia. , 2007, Journal of the American Society of Nephrology : JASN.
[56] P. McKenzie,et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. , 2007, Kidney international.
[57] Asif Ahmed,et al. Negative Regulation of Soluble Flt-1 and Soluble Endoglin Release by Heme Oxygenase-1 , 2007, Circulation.
[58] G. Saade,et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. , 2007, American journal of obstetrics and gynecology.
[59] A. Baschat,et al. Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. , 2007, American journal of perinatology.
[60] K. Bailey,et al. Urinary podocyte excretion as a marker for preeclampsia. , 2007, American journal of obstetrics and gynecology.
[61] M. Wolf,et al. Agonistic Angiotensin II Type 1 Receptor Autoantibodies in Postpartum Women With a History of Preeclampsia , 2007, Hypertension.
[62] K. Lim,et al. Circulating Levels of the Antiangiogenic Marker Soluble FMS-Like Tyrosine Kinase 1 Are Elevated in Women With Pregestational Diabetes and Preeclampsia , 2007, Diabetes Care.
[63] S. Karumanchi,et al. Endothelial Dysfunction: A Link Among Preeclampsia, Recurrent Pregnancy Loss, and Future Cardiovascular Events? , 2007, Hypertension.
[64] Caroline A Crowther,et al. Spontaneous preterm delivery in primiparous women at low risk in Denmark: population based study , 2006, BMJ : British Medical Journal.
[65] B. Sibai,et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. , 2006, The New England journal of medicine.
[66] J. Thurman,et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction , 2006, The Journal of experimental medicine.
[67] J. Hanna,et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface , 2006, Nature Medicine.
[68] F. Epstein,et al. Circulating Angiogenic Factors and Placental Abruption , 2006, Obstetrics and gynecology.
[69] T. Libermann,et al. Soluble endoglin contributes to the pathogenesis of preeclampsia , 2006, Nature Medicine.
[70] L. Poston,et al. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial , 2006, The Lancet.
[71] F. Epstein,et al. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. , 2006, American journal of obstetrics and gynecology.
[72] A. Coomarasamy,et al. Accuracy of serum uric acid in predicting complications of pre‐eclampsia: a systematic review , 2006, BJOG : an international journal of obstetrics and gynaecology.
[73] G. Pacini,et al. Preeclampsia in Lean Normotensive Normotolerant Pregnant Women Can Be Predicted by Simple Insulin Sensitivity Indexes , 2006, Hypertension.
[74] M. Saint-Geniez,et al. Vascular endothelial growth factor localization in the adult. , 2006, The American journal of pathology.
[75] G. Krikun,et al. Regulation of monocyte chemoattractant protein-1 expression by tumor necrosis factor-alpha and interleukin-1beta in first trimester human decidual cells: implications for preeclampsia. , 2006, The American journal of pathology.
[76] Betty Y. Y. Tam,et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. , 2006, American journal of physiology. Heart and circulatory physiology.
[77] C. Ozcan,et al. Reversible posterior leukoencephalopathy syndrome and bevacizumab. , 2006, The New England journal of medicine.
[78] J. Granger,et al. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. , 2006, Methods in molecular medicine.
[79] M. Schull,et al. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study , 2005, The Lancet.
[80] K. Lim,et al. Circulating Angiogenic Factors in the Pathogenesis and Prediction of Preeclampsia , 2005, Hypertension.
[81] Michael Simons,et al. Role of Angiogenesis in Cardiovascular Disease : a Critical Appraisal , 2022 .
[82] M. Wolf,et al. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. , 2005, Placenta.
[83] R. Ness,et al. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. , 2005, American journal of obstetrics and gynecology.
[84] I. Sargent,et al. Latest Advances in Understanding Preeclampsia , 2005, Science.
[85] Kirsten Duckitt,et al. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies , 2005, BMJ : British Medical Journal.
[86] G. Mires,et al. In Preeclampsia, the Circulating Factors Capable of Altering In Vitro Endothelial Function Precede Clinical Disease , 2005, Hypertension.
[87] B. Sibai. Diagnosis, prevention, and management of eclampsia. , 2005, Obstetrics and gynecology.
[88] K. Lim,et al. Urinary placental growth factor and risk of preeclampsia. , 2005, JAMA.
[89] R. Romero,et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia , 2005, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[90] E. Norwitz,et al. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. , 2004, American journal of obstetrics and gynecology.
[91] J. Norman. The nature of glomerular dysfunction in preeclampsia , 2005 .
[92] M. Wolf,et al. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. , 2004, The Journal of clinical endocrinology and metabolism.
[93] S. Kōzuma,et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. , 2004, Endocrinology.
[94] Asif Ahmed,et al. Elevated Placental Soluble Vascular Endothelial Growth Factor Receptor-1 Inhibits Angiogenesis in Preeclampsia , 2004, Circulation research.
[95] M. Carrington,et al. Combinations of Maternal KIR and Fetal HLA-C Genes Influence the Risk of Preeclampsia and Reproductive Success , 2004, The Journal of experimental medicine.
[96] M. Goumans,et al. Endoglin promotes endothelial cell proliferation and TGF‐β/ALK1 signal transduction , 2004, The EMBO journal.
[97] L. Poston,et al. Oxidative stress and preeclampsia: rationale for antioxidant clinical trials. , 2004, Hypertension.
[98] N. Berkane,et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. , 2004, Clinical chemistry.
[99] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[100] R. Romero,et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. , 2004, American journal of obstetrics and gynecology.
[101] K. Lim,et al. Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.
[102] Robert N. Taylor,et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. , 2004, The Journal of clinical endocrinology and metabolism.
[103] J. Foidart,et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. , 2003, The Journal of clinical endocrinology and metabolism.
[104] T. Libermann,et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. , 2003, The Journal of clinical investigation.
[105] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[106] N. Sattar,et al. Classic and Novel Risk Factor Parameters in Women With a History of Preeclampsia , 2003, Hypertension.
[107] Christoph Dehio,et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 , 2003, Nature Medicine.
[108] Y. Taketani,et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. , 2003, The Journal of clinical endocrinology and metabolism.
[109] G. Prescott,et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study , 2003, BMJ : British Medical Journal.
[110] J. Haigh,et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. , 2003, The Journal of clinical investigation.
[111] Kenneth J. Hillan,et al. Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1 , 2003, Science.
[112] A. Hughes,et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution , 2002, The Lancet.
[113] N. Sattar,et al. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? , 2002, BMJ : British Medical Journal.
[114] M. Wolf,et al. First trimester insulin resistance and subsequent preeclampsia: a prospective study. , 2002, The Journal of clinical endocrinology and metabolism.
[115] M. Goumans,et al. Balancing the activation state of the endothelium via two distinct TGF‐β type I receptors , 2002, The EMBO journal.
[116] Diagnosis and management of preeclampsia and eclampsia , 2002 .
[117] G. Dekker,et al. Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia , 2002, The Lancet.
[118] R. T. Lie,et al. The interval between pregnancies and the risk of preeclampsia. , 2002, The New England journal of medicine.
[119] A. Luttun,et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.
[120] M. Wolf,et al. Obesity and preeclampsia: the potential role of inflammation. , 2001 .
[121] J. Pell,et al. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births , 2001, The Lancet.
[122] Till Acker,et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions , 2001, Nature Medicine.
[123] R. Thadhani,et al. Pulse Pressure and Risk of Preeclampsia: A Prospective Study , 2001, Obstetrics and gynecology.
[124] C. Berg,et al. Pregnancy‐Related Mortality From Preeclampsia and Eclampsia , 2001, Obstetrics and gynecology.
[125] J. Kooner,et al. Association of maternal endothelial dysfunction with preeclampsia. , 2001, JAMA.
[126] M. Varner,et al. Paternal and maternal components of the predisposition to preeclampsia. , 2001, The New England journal of medicine.
[127] James J. Walker,et al. Pre-eclampsia , 2000, The Lancet.
[128] D. Stevenson,et al. End-tidal carbon monoxide measurements in women with pregnancy-induced hypertension and preeclampsia. , 2000, American journal of obstetrics and gynecology.
[129] P. Donahoe,et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[130] C. O'Herlihy,et al. Maternal central hemodynamics in hypertensive disorders of pregnancy. , 1999, Obstetrics and gynecology.
[131] C. Hubel,et al. Oxidative Stress in the Pathogenesis of Preeclampsia (44447) , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[132] D. Dumont,et al. A murine model of hereditary hemorrhagic telangiectasia. , 1999, The Journal of clinical investigation.
[133] H. V. van Geijn,et al. Change in paternity: a risk factor for preeclampsia in multiparous women? , 1999, Journal of reproductive immunology.
[134] A. Conde-Agudelo,et al. Cigarette smoking during pregnancy and risk of preeclampsia: a systematic review. , 1999, American journal of obstetrics and gynecology.
[135] J. N. Martin,et al. Maternal mortality associated with HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. , 1999, American journal of obstetrics and gynecology.
[136] M. Marrero,et al. Vascular Endothelial Growth Factor Signals Endothelial Cell Production of Nitric Oxide and Prostacyclin through Flk-1/KDR Activation of c-Src* , 1999, The Journal of Biological Chemistry.
[137] R. Dersimonian,et al. Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. , 1999, JAMA.
[138] L. Moore,et al. Altered blood pressure course during normal pregnancy and increased preeclampsia at high altitude (3100 meters) in Colorado. , 1999, American journal of obstetrics and gynecology.
[139] G. Wallukat,et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. , 1999, The Journal of clinical investigation.
[140] M Aguet,et al. VEGF is required for growth and survival in neonatal mice. , 1999, Development.
[141] A. N. Corps,et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. , 1998, Biology of reproduction.
[142] P. Huie,et al. Nature of glomerular dysfunction in pre-eclampsia1 , 1998 .
[143] T. Noda,et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[144] I. Sargent,et al. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre‐eclamptic pregnancies , 1998, British journal of obstetrics and gynaecology.
[145] K. Lim,et al. The clinical utility of serum uric acid measurements in hypertensive diseases of pregnancy. , 1998, American journal of obstetrics and gynecology.
[146] Vascular Endothelial Growth Factor Induces Endothelial Fenestrations In Vitro , 1998, The Journal of cell biology.
[147] I. Zachary,et al. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen‐activated protein kinase , 1997, FEBS letters.
[148] I. Johnson,et al. Loss of endothelium‐dependent relaxation in myometrial resistance arteries in pre‐eclampsia , 1997, British journal of obstetrics and gynaecology.
[149] N. Ferrara,et al. Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes , 1997, The Journal of Biological Chemistry.
[150] C. Damsky,et al. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? , 1997, The Journal of clinical investigation.
[151] M. Taketo,et al. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. , 1996, Developmental biology.
[152] R. Kendall,et al. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. , 1996, Biochemical and biophysical research communications.
[153] H. Laivuori,et al. Hyperinsulinemia 17 years after preeclamptic first pregnancy. , 1996, The Journal of clinical endocrinology and metabolism.
[154] Kenneth J. Hillan,et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.
[155] B. Keyt,et al. Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors , 1996, The Journal of Biological Chemistry.
[156] J. Flanagan,et al. Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor , 1996, The Journal of Biological Chemistry.
[157] C. Damsky,et al. Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. , 1996, The Journal of clinical investigation.
[158] E. Arnoldus,et al. A reversible posterior leukoencephalopathy syndrome. , 1996, The New England journal of medicine.
[159] R. Berkowitz,et al. The Changing Clinical Presentation of Complete Molar Pregnancy , 1995, Obstetrics and gynecology.
[160] J. Pezzullo,et al. Placental pathologic features of preterm preeclampsia. , 1995, American journal of obstetrics and gynecology.
[161] Janet Rossant,et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.
[162] M. Blombäck,et al. Plasma levels of von Willebrand factor and fibronectin as markers of persisting endothelial damage in preeclampsia , 1995 .
[163] M. Shibuya,et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.
[164] J. Winer,et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. , 1994, The Journal of biological chemistry.
[165] R. North,et al. Uterine Artery Doppler Flow Velocity Waveforms in the Second Trimester for the Prediction of Preeclampsia and Fetal Growth Retardation , 1994, Obstetrics and gynecology.
[166] D. W. Johnson,et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 , 1994, Nature Genetics.
[167] R. Kendall,et al. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[168] B. Sibai,et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome) , 1993, American journal of obstetrics and gynecology.
[169] S. Liu,et al. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. , 1993, The American journal of physiology.
[170] D. Chan,et al. Elevated circulating thrombomodulin in severe preeclampsia. , 1993, American journal of obstetrics and gynecology.
[171] H. Minakami,et al. Increased levels of plasma thrombomodulin in preeclampsia. , 1993, Gynecologic and obstetric investigation.
[172] L. Poston,et al. Abnormal endothelial cell function of resistance arteries from women with preeclampsia. , 1993, American journal of obstetrics and gynecology.
[173] C. Damsky,et al. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. , 1993, The Journal of clinical investigation.
[174] Caroline,et al. Distribution patterns of extracellular matrix components and adhesion receptors are intricately modulated during first trimester cytotrophoblast differentiation along the invasive pathway, in vivo. , 1992, The Journal of clinical investigation.
[175] G. Viglietto,et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[176] J. Roberts,et al. High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. , 1991, American journal of obstetrics and gynecology.
[177] I. Sargent,et al. Trophoblast deportation in pre‐eclamptic pregnancy , 1991, British journal of obstetrics and gynaecology.
[178] M. Mitchell,et al. Maternal plasma level of endothelin is increased in preeclampsia. , 1991, American journal of obstetrics and gynecology.
[179] D. Maglione. Persico MG.Isolation of a human placenta cDNA coding for a potein related to the vascular premeability factor , 1991 .
[180] J. Moake,et al. Von Willebrand Factor Multimeric Levels and Patterns in Patients With Severe Preeclampsia , 1990, Obstetrics and Gynecology.
[181] D. Savitz,et al. An epidemiologic study of contraception and preeclampsia. , 1991, JAMA.
[182] D. Goeddel,et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.
[183] D. Connolly,et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. , 1989, Science.
[184] T. Musci,et al. Preeclampsia: an endothelial cell disorder. , 1989, American journal of obstetrics and gynecology.
[185] T. Musci,et al. Mitogenic activity is increased in the sera of preeclamptic women before delivery. , 1988, American journal of obstetrics and gynecology.
[186] J. Roberts,et al. Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. , 1988, American journal of obstetrics and gynecology.
[187] G. FitzGerald,et al. Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension. , 1987, Circulation.
[188] Ishak Kg,et al. Liver disease in toxemia of pregnancy. , 1986 .
[189] K. Ishak,et al. Liver disease in toxemia of pregnancy. , 1986, The American journal of gastroenterology.
[190] T. Stubbs,et al. Plasma fibronectin levels in preeclampsia: a possible biochemical marker for vascular endothelial damage. , 1984, American journal of obstetrics and gynecology.
[191] L. Weinstein. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. , 1982, American journal of obstetrics and gynecology.
[192] J. Brown,et al. Plasma renin, renin substrate, angiotensin II, and aldosterone in hypertensive disease of pregnancy. , 1973, Lancet.
[193] D. Paintin,et al. Renin, Angiotensin and Aldosterone Relationships in Normal Pregnancy , 1970, Proceedings of the Royal Society of Medicine.
[194] M. Rinsler,et al. Function of Aldosterone in the Metabolism of Sodium and Water in Pregnancy , 1957, British medical journal.